Santiago Diaz Mejia, Founder and President“By bringing together various stakeholders—through our case management model, we partner with insurance companies, hospitals, patients and physicians within the biopharmaceutical ecosystem—we strive to collectively overcome barriers to providing patients with the right treatments, especially for rare diseases,” says Santiago Diaz Mejia, founder and president.
Optimal Therapies addresses delayed access to treatments in less developed markets like Latin America, recognizing that these therapies are typically launched first in mature markets such as the U.S. and Europe. The question arises—how can patients obtain the required therapies when these treatments are unavailable locally?
To answer this, Optimal Therapies conducted a comprehensive analysis of barriers to medication access and discovered that many patients lacked access to therapies due to the rarity of their conditions and the absence of licensed manufacturers or distributors. By collaborating closely with key stakeholders,
The company’s app plays a vital role in the process. It searches for national and international suppliers when a specific treatment is not found. If unavailable locally, it provides the best offers to hospitals, government entities and health insurance companies, considering price and compliance with legal terms. This process generates savings and speeds up access to therapies, confirming patients receive the best possible care.
Clear communication with doctors and payers, including health insurance companies and hospitals, is a cornerstone of Optimal Therapies’ approach. This transparency ensures that patients undergoing expensive and complex treatments adhere to their treatment plans. For payers, this approach guarantees effective utilization of investments, as proper follow-up leads to better health outcomes and more efficient resource use.
The company’s two main layers—supply and specialty pharmacy—ensure full traceability of medications from origin to arrival in Colombia, covering temperature control and regulations such as customs clearance. Following dispensing, Optimal Therapies oversees infusion at hospitals and homes, maintaining detailed records of the medication’s journey and patient impact. This thorough tracking benefits biotech manufacturers and assures payers, such as governments and insurance companies, of sound investments, reducing the risk of worsening conditions and unnecessary emergency room visits.
We understand the importance of equipping patients with the right treatments, especially within the rare disease sector and ensuring that doctors are well-informed and prepared to manage these complex therapies
Optimal Therapies showcased remarkable results in treating cystic fibrosis, reducing medication intake by 77 percent and increasing the quality of life by 2.8 percent. Its follow-up ensured 100 percent control over respiratory symptoms, while 78.5 percent of patients saw nutritional recovery. Emergency room visits dropped from 1.5 to zero for 10 patients, yielding significant cost savings. This exemplifies Optimal Therapies’ dedication to transformative patient care and tangible outcomes.
In healthcare, Optimal Therapies is the guiding thread that merges innovation, compassion and accessibility. It redefines rare disease management and transforms lives, offering hope and care to every patient, regardless of their circumstances. Optimal Therapies is not just providing treatments but illuminating a path toward a healthier, more equitable future for all.
